Together, these findings on treatment patterns suggest that rheumatologists and other clinicians may require additional education on the changing therapeutic paradigms for AOSD, particularly with respect to IL-1 and IL-6R inhibitors as effective tools in the management of this disorder. This evidence concerns the gene IL6R and adult-onset Still disease.